Indication
Amyloidosis
20 clinical trials
16 products
5 drugs
Product
VenetoclaxProduct
PatisiranClinical trial
HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)Status: Active (not recruiting), Estimated PCD: 2020-11-10
Product
VutrisiranClinical trial
A Single Arm, Open-Label, Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) AmyloidosisStatus: Active (not recruiting), Estimated PCD: 2025-05-01
Product
ZN-d5Clinical trial
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)Status: Completed, Estimated PCD: 2017-08-01
Product
Sterile Normal SalineClinical trial
An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) With Disease Progression Post-Orthotopic Liver TransplantStatus: Completed, Estimated PCD: 2020-10-06
Clinical trial
An Open-label, Multi-center, Non-randomized Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of [18F]Florbetaben Positron Emission Tomography (PET) Imaging to Diagnose Cardiac AL AmyloidosisStatus: Recruiting, Estimated PCD: 2025-03-01
Product
[18F]florbetabenProduct
IxazomibClinical trial
An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib StudiesStatus: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
A Phase Ib/II Open-Label Study of APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma and Immunoglobin Light Chain AmyloidosisStatus: Recruiting, Estimated PCD: 2024-09-01
Product
APG-2575Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects With Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM Trial)Status: Completed, Estimated PCD: 2023-05-11
Product
PlaceboProduct
acoramidisProduct
InotersenClinical trial
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy (FAP)Status: Completed, Estimated PCD: 2020-09-11
Clinical trial
A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients With Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Patisiran Clinical StudyStatus: Completed, Estimated PCD: 2022-11-23
Clinical trial
Phase 1/2 Trial of Ixazomib in Combination With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain AmyloidosisStatus: Active (not recruiting), Estimated PCD: 2021-04-30
Drug
cyclophosphamideProduct
DexamethasoneClinical trial
Expanded Access Protocol of Patisiran for Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR Amyloidosis) With PolyneuropathyStatus:
Clinical trial
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic AL AmyloidosisStatus: Active (not recruiting), Estimated PCD: 2020-02-14
Product
BortezomibProduct
DaratumumabClinical trial
A Dose-Finding and Proof-of-Concept Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL AmyloidosisStatus: Recruiting, Estimated PCD: 2026-03-01
Product
Belantamab mafodotinClinical trial
Pharmacokinetic (PK)-Directed Dosing of Captisol Enabled Melphalan for Patients With Multiple Myeloma or Light Chain (AL) Amyloidosis Undergoing High Dose Therapy and Autologous Hematopoietic Progenitor Cell TransplantStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Product
PegfilgrastimClinical trial
Desensitization of Immunomodulating Agent-Related Hypersensitivity Reactions as a Means to Provide Therapeutic Options in the Management of Plasma Cell Disorders (DeHyperPCD)Status: Completed, Estimated PCD: 2022-06-30
Drug
lenalidomideDrug
PomalidomideClinical trial
A Pilot/Feasibility Trial of 64Cu-DOTA-Daratumumab Positron Emission Tomography in Patients With Newly Diagnosed or Relapsed Multiple MyelomaStatus: Completed, Estimated PCD: 2020-01-22
Drug
89Zr-DFO-YS5Clinical trial
A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) AmyloidosisStatus: Recruiting, Estimated PCD: 2024-11-29
Drug
bortezomibClinical trial
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic AL AmyloidosisStatus: Active (not recruiting), Estimated PCD: 2020-02-14